Contact Information: SCYNEXIS Media Contact: Rick Rountree Rick Rountree Communications (919) 878-1144 Email Contact SCYNEXIS Market Development Contact: Terry Marquardt (919) 544-8600 Email Contact
SCYNEXIS Announces Research Agreement With Merck for Discovery of Novel Oncology Agents
| Source: SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- December 6, 2006 --SCYNEXIS, Inc., a
chemistry-focused drug discovery and development company, today announced
that it has entered into a multi-year research agreement with Merck & Co.,
Inc. to discover and develop novel oncology compounds.
Through the use of its proprietary technologies, SCYNEXIS will produce
highly-targeted compound libraries and utilize rapid lead optimization
techniques to develop new drug candidates for clinical evaluation.
"SCYNEXIS is pleased to carry on our successful relationship with Merck by
collaborating in this new area of research," said Dr. Yves J. Ribeill,
president & chief executive officer of SCYNEXIS.
About SCYNEXIS
SCYNEXIS is a chemistry-focused drug discovery and development company with
its headquarters located in Research Triangle Park, North Carolina.
SCYNEXS' goal, from concept to clinic, is to deliver effective and
innovative drug pipeline solutions to our pharmaceutical partners.
SCYNEXIS' research teams integrate computational chemistry, medicinal
chemistry, bioanalysis and process chemistry. SCYNEXIS teams use powerful,
proprietary technologies such as the HEOS® Software Suite,
MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to optimize lead
molecules for candidate selection. SCYNEXIS process chemistry and
bioanalytical departments operate under current GMP/GLP guidelines and have
established a strong track record of success. SCYNEXIS tailors its teams
to be especially effective in moving customer projects from the discovery
phase to clinical proof of concept.
For more information, please go to www.scynexis.com